Junshi Bio FY net loss 875.2M yuan

Junshi Biosciences (01877.HK) reported preliminary full-year 2025 financial results, showing total revenue of RMB 2.498 billion, reflecting a 28.2% year-on-year increase compared to RMB 1.948 billion in the prior year. Despite this revenue growth, the company recorded a net loss of RMB 874 million, a reduction from RMB 1.281 billion in 2024. The narrowing loss indicates improved financial performance but underscores continued operational challenges in the biopharmaceutical sector. Basic loss per share for the year was RMB 0.87, down from RMB 1.30 in the previous fiscal year. The results highlight the company's focus on revenue expansion amid ongoing efforts to manage costs and R&D expenditures. Investors may note that while the decline in net loss signals progress, profitability remains elusive, consistent with industry trends where significant investment in drug development often precedes commercial gains. The data, preliminary in nature, align with broader market dynamics in biotechnology, where scaling revenue and achieving profitability typically require extended timelines. As of March 13, 2026, the company has not disclosed further details on strategic initiatives or future financial projections.

Junshi Biosciences FY 2025 revenue and loss figures: Junshi Biosciences FY 2025 revenue and loss figures.
Shanghai Junshi Biosciences Co., Ltd. earnings report for the full year ended December 31, 2025: Shanghai Junshi Biosciences Co., Ltd. earnings report for the full year ended December 31, 2025.